secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2026-08-05T12:02:32+00:00
Accession:  0001437749-26-025793
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Q2 2026: ZUSDURI revenue $50.4M (+73% QoQ); net loss narrows to $14.4M
-----------------------------------------------------------------------------

- Total revenue $72.5M (Q2 2026) vs $24.2M (Q2 2025), driven by ZUSDURI launch.
- ZUSDURI net product revenue $50.4M, 73% QoQ growth; 1,444 activated sites, 452 prescribers.
- JELMYTO revenue $22.0M (Q2 2026) vs $24.2M (Q2 2025); FY guidance $97-101M.
- Net loss $14.4M ($0.28/share) vs $49.9M ($1.05) in Q2 2025; cash $108.0M.
- UGN-103 NDA on track for Q3 2026; new patent allowance extends ZUSDURI protection to July 2044.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/0001437749-26-025793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/urgn20260730_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-025793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer